{"disease":{"id":"chronic-kidney-disease-ckd-associated-with-type-2-diabetes-t2d","name":"chronic kidney disease ckd associated with type 2 diabetes t2d"},"drugs":{"marketed":[{"drug_id":"canagliflozin","indication_name":"Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invokana","generic_name":"CANAGLIFLOZIN","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":71,"revenue":"800","mechanism":"Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption."},{"drug_id":"finerenone","indication_name":"Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kerendia","generic_name":"FINERENONE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]","quality_score":59,"revenue":"600","mechanism":"Kerendia works by blocking the mineralocorticoid receptor, a protein that regulates sodium and potassium levels in the body."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}